OrisDX Announces the Official launch of Oro Lesion

| |
2 Minutes
OrisDX Announces the Official launch of Oro Lesion
4:43


First time a DNA-based precision diagnostic is launched into the dental setting where the patient journey begins.

CHICAGO, IL — Nov 16, 2026 — OrisDX announces today that Oro Lesion, the company’s noninvasive saliva DNA test, is available as a Laboratory Developed Test regulated under the Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvement Amendments (CLIA) certification and the College of American Pathologists (CAP) accreditation process. Oro Lesion is the first noninvasive test for oral cavity squamous cell carcinoma (OCSCC) that analyzes DNA from a saliva-based sample and has been proven to have 94% sensitivity, 98% specificity, a positive predictive value of 96%, and a negative predictive value of 97%. Oro Lesion, available through dental and medical providers, offers people over 18 years old with an indeterminate oral lesion an easy-to-use test they can take in a clinic or in the privacy of their own home.

Head and neck cancer is the sixth most common cancer globally, yet late-stage diagnosis leaves patients with 5-year survival rates as low as 25%. Approximately 1.6 million to 4.9 million adults over the age of 18 are seen by a dentist with an oral lesion that may be cancerous. If detected earlier, the lesion can be removed, with survival as high as 90%.

 

“As a head and neck cancer survivor, I know how hard it can be to wait for answers when you notice a change in your mouth. Getting it checked promptly by a dental or medical professional and knowing what comes next can make a real difference for patients and their families."

— Cathy Hapenney, head and neck cancer survivor and advocate

 

Oro Lesion is designed to detect biomarkers from acquired (somatic) mutations in cancer-related DNA in whole cells collected by agitation of a salivary rinse. A clinician can collect the sample with the Oro Lesion Collection Kit after seeing the lesion during a conventional oral examination, or the kit can be mailed directly to the patient’s home. The salivary sample is sent back to the OrisDX lab for testing through a pre-paid mailer.

At the lab, the salivary sample is analyzed in an automated system to yield a single test result–detected or not-detected for the presence of the biomarkers associated with OCSCC. Results from the Oro Lesion test are turned around in as little as two weeks, and Oris Bridge shares them with the prescribing clinician and patient. If the test is positive, the patient navigation system will support the patient's journey to a surgeon. There are no restrictions or experience needed to collect the sample.

 

“Oral cancer is most treatable when it’s caught early, and too many cases aren’t. OrisDX gives clinicians a simple, noninvasive way to find it sooner, with accuracy we have validated in a CLIA-certified, CAP-accredited lab. We designed the test to be accurate, easy for patients to use, and widely accessible,” said Nishant Agrawal, M.D., a UChicago Medicine surgeon and co-inventor of the test.

“Our hope is that earlier detection will save lives.”

 — Nishant Agrawal, M.D.

 

"For far too long, patients facing a suspicious oral lesion have found themselves caught in a fragmented gray zone between routine dental care and complex medical oncology—facing anxiety, delays, and invasive unknowns,” said Harald Steltzer, CEO of OrisDX. “With the launch of Oro Lesion, we are directly closing that divide. By arming clinicians with definitive, non-invasive molecular clarity at the earliest point of concern, we aren’t just advancing diagnostics; we are fundamentally reshaping the patient journey. Our mission is to put the individual first, replacing prolonged uncertainty with swift, actionable answers, and ensuring that every patient seamlessly navigates from the dental chair to the right specialized care without falling through the cracks."

Oro Lesion is available to patients through their healthcare providers in the US. OrisDX has plans to add HPV biomarkers to the test for multicancer detection, which is typically found in the oropharynx. For more information, visit www.orisdx.com/orolesion or call 1-464-888-3940.

_______

Dr. Nishant Agrawal, Chair, Department of Otolaryngology-Head and Neck Surgery, UChicago Medicine, is the inventor of the technology that has been licensed to OrisDX from the University of Chicago Polsky Center. Under the licensing agreement, the University of Chicago and Dr. Agrawal shares in equity and royalties.

Have a Question or Need Guidance?

Our health experts are here to help you! Send us your query and we’ll get back within 24 hours.